Neurocrine leaps on strong Ingrezza sales

Neurocrine Biosciences Inc. (NASDAQ:NBIX) rose $11.85 (19%) to $72.78 on Thursday after reporting strong sales of Ingrezza valbenazine in its first full quarter on the U.S. market. The move equated to an additional $1 billion in market cap for Neurocrine.

Ingrezza sales were $45.8 million in 3Q17, beating consensus estimates of $12.9 million. In the earnings call late Wednesday, Neurocrine VP of Finance Timothy Coughlin said prescription volume has grown month-over-month since the drug's launch on May 1...